Drugmaker cuts prices for Ozempic, Wegovy. Here's how much you will pay.

Novo Nordisk cut prices for most injectable Wegovy and Ozempic formulations to $349 a month from $499 (the 2 mg Ozempic remains $499), and is offering new self-pay customers 0.25 mg and 0.5 mg starter packs for $199 for the first two months through March 31, 2026. The move follows pressure from the Trump administration and a Medicare deal tied to the upcoming TrumpRx program, and comes amid competition from compounding pharmacies and ongoing affordability issues—Wegovy's list price is $1,349 and many users still pay full cost; roughly 44% of large employers now cover GLP-1s for obesity and about 1 in 8 U.S. adults use a GLP-1. Novo is widening retail and discount distribution (Costco, Sam’s Club, GoodRx, NovoCare) and expects an oral Wegovy pill by early 2026, steps that should boost volume and access and intensify pricing and competitive dynamics in the GLP-1 market, including vs. Lilly.

Analysis

Novo Nordisk cut prices for most injectable Wegovy and Ozempic to $349 per month from $499 effective Nov. 17, while keeping the 2 mg Ozempic dose at $499; new self-pay customers can buy 0.25 mg and 0.5 mg starter packs for $199 for the first two months through March 31, 2026. The company is expanding retail and discount distribution through Costco, Sam’s Club, GoodRx and NovoCare as part of an access strategy it says will drive volume growth.

The price action follows pressure from the Trump administration and a Nov. 6 Medicare-related agreement that will have Wegovy covered for older adults and feed into the TrumpRx direct-to-consumer site launching in 2026; Novo also faces competition from compounding pharmacies selling lower-cost semaglutide. Affordability remains a constraint: Wegovy’s list price is $1,349, roughly 1 in 8 U.S. adults use GLP-1s, about 25% of users pay full cost, and more than half report difficulty affording these drugs.

Lower list prices and broader retail access should increase volumes, but the mix shift to discounted injectables and planned lower-cost oral formulations (targeted availability early 2026) will likely compress average selling prices and margins unless uptake and payer coverage expand materially. Key downside risks are accelerated competitive pricing (including Lilly’s oral program) and sustained penetration of compounded alternatives that undercut branded pricing.

Key Decisions for Investors

• Reassess revenue and margin models for Novo Nordisk to reflect lower ASPs from $499 to $349 for most injectables and the $199 introductory offers, and model higher volumes but lower per-unit revenue through 2026
• Monitor Medicare implementation of the Nov. 6 deal and the TrumpRx launch timetable as potential catalysts for accelerated price competition and broader self-pay demand, and adjust exposure if coverage expansion is confirmed
• Track FDA progress on Novo's oral Wegovy and Lilly's oral GLP-1 program and retail rollout metrics (Costco, Sam's Club, GoodRx) as key inflection points for volume growth and competitive share shifts
• Consider tactical hedges or trimming near-term long exposure to names most exposed to margin compression if evidence of declining ASPs and higher discount penetration intensifies, while maintaining selective exposure to beneficiaries of increased patient volume and insurer coverage